Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus epacadostat versus pembrolizumab plus placebo in unresectable or metastatic melanoma
2015-004991-31Phase 3Completed
- Sponsor
- Incyte
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab + epacadostat with Pembrolizumab + placebo (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Mar 2016; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-004991-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004991-31.